Mesenchymal stem cell therapy in patients with severe myocardial ischemia - Stem celle therapy in ischemic heart disease

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2005-002657-45-DK

Enrollment

Registered

2005-08-15

Start date

2005-10-24

Completion date

Unknown

Last updated

2021-05-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic coronary artery disease

Interventions

Product Name: Autologous mesenchymale stem cell Product Code: msc1 Pharmaceutical Form: Solution for injection Pharmaceutical form of the placebo: Concentrate for solution for injection Route of admin

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Age between 30 and 80 years Modrate to severe angina pectoris CCC class > II Reversible ischemia on SPECT Reduced exercise capacity due to angina No further revascularization options Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: Pregnant women Abnormal blood tests Reduced kidney function (serum Creatinine > 1,7 mg/dl) Proliferativ retinopati Left ventricle ejektions fraction < 25% NYHA-klasse III-IV Valvular heart disease Malignant disease

Design outcomes

Primary

Measure	Time frame
Main Objective: To induce vasculogenesis and improve blood flow in ischemic myocardium by treatment with autologous mesenchymal stem cells.;Secondary Objective: ;Primary end point(s): Improvement in myocardial blood flow by SPECT	—

Countries

Denmark

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026